We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Roche’s DNA Sequencer Opens Innovation in Genomic Research to Broad Scientific Community

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Roche’s DNA Sequencer Opens Innovation in Genomic Research to Broad Scientific Community"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roche has announced the global launch of the GS Junior System, the company’s new benchtop next-generation DNA sequencing platform for life science research.

The GS Junior System, developed by 454 Life Sciences, a Roche company, provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. Due to its size and efficiency thousands of small and medium sized research laboratories worldwide will now have access to Roche’s sequencing capabilities at an affordable price, the company said.

The GS Junior System offers solutions for DNA sequencing in nearly every field of biological research including human population genetics, agricultural and environmental genomics and particularly for research in the area of human health. The system is suited for research labs that require targeted sequencing of genomic regions associated with diseases such as diabetes and cancer, whole microbial genome sequencing, metagenomic analysis, as well as novel pathogen detection. That technology also offers significant advantages over current standards in many areas of medical research, such as in tissue matching for transplantation and HIV drug resistance detection.

“Roche has a proven track record of delivering innovative solutions in both life science research and diagnostics. With its fast turn around time and high sensitivity we expect the GS Junior System to provide significant medical value in future diagnostic applications,” said Daniel O’Day, Chief Operating Officer of Roche Diagnostics. “Putting the GS Junior System into hands of researchers worldwide will help to expand our knowledge of the genetic causes and molecular basis of diseases thereby contributing to the development of personalized healthcare.”

DNA sequencing is a large growth opportunity, particularly in the areas of oncology where elucidation of new mutations and gene rearrangements offer greater insights into disease mechanisms and potential areas for drug discovery. Currently, the global sequencing business is worth over one billion Swiss francs, with substantial double digit growth expected for the next several years.